---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000064"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-08-28T21:08:50+00:00"
generated_at: "2026-08-28T21:10:06.061936+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cumberland delays release of FIGHT DMD ifetroban long-term data; no new timeline

## Summary
- Phase 2 FIGHT DMD open-label extension long-term safety/efficacy data for ifetroban not yet available.
- Company no longer expects to present data in August 2026 as stated at PPMD conference on June 26, 2026.
- Data was originally expected at Parent Project Muscular Dystrophy annual conference in Orlando.
- Cumberland will present at a future date when data becomes available; no revised timeline given.
- Ifetroban is an oral candidate for Duchenne muscular dystrophy heart disease.

## SEC filing metadata
- accession: 0001087294-26-000064
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-08-28T21:08:50+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/0001087294-26-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000064/cpix-20260828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000064
- JSON: https://secwatch.observer/filing/0001087294-26-000064.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.